Universal Health Services stock outlook improves as Cantor maintains neutral rating

Published 30/07/2025, 16:32
Universal Health Services stock outlook improves as Cantor maintains neutral rating

Investing.com - Cantor Fitzgerald maintained its Neutral rating and $227.00 price target on Universal Health Services (NYSE:UHS) on Wednesday, citing a clearer pathway to EBITDA growth in 2026 versus 2025. According to InvestingPro data, UHS currently trades at an attractive P/E ratio of 8.42x and maintains a GREAT financial health score.

The research firm expressed increased optimism about UHS’s 2026 EBITDA growth prospects, highlighting a $50 million tailwind expected from Cedar Hill recovery. This recovery is anticipated to contribute $25 million in the second quarter of 2025 and another $25 million in the second half of 2025, building upon the company’s current EBITDA of $2.34 billion and impressive 9.73% revenue growth.

Cantor Fitzgerald also noted that the $1.2 billion Directed Payment Program (DPP) benefit in 2025 has the potential to remain flat rather than decline in 2026, excluding a possible tailwind from D.C. DPP approval. For deeper insights into UHS’s financial health and growth prospects, check out the comprehensive Pro Research Report available on InvestingPro.

The firm cautioned against excessive optimism regarding a potential fix to enhanced Health Insurance Exchange (HIX) subsidies, which are currently scheduled to expire.

Universal Health Services joins Tenet Healthcare (NYSE:THC) and HCA Healthcare (NYSE:HCA) in leaving the impact of the HIX subsidies expiration unsized in their outlooks, which Cantor noted contrasts with health insurance companies that are all assuming the subsidies will expire as current legislation indicates.

In other recent news, Universal Health Services reported its second-quarter 2025 earnings, surpassing expectations with an adjusted earnings per share of $5.35. This figure exceeded the forecasted $4.93, marking an 8.52% surprise. Revenue also outperformed projections, reaching $4.28 billion compared to the anticipated $4.24 billion. Furthermore, the company posted adjusted EBITDA that exceeded consensus estimates by 5%, despite a $25 million impact from its DC hospital operations during the quarter. In terms of analyst ratings, TD Cowen has maintained its Buy rating on Universal Health Services, with a price target of $226. These developments indicate continued positive momentum for the healthcare services provider.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.